Obi Mukosolu F, Sharma Manjari, Namireddy Vikhyath, Patel Vyoma, Reinberg Palmar Arianna, Kanu Ngozi T
Internal Medicine, Wyckoff Heights Medical Center, Brooklyn, USA.
Medicine, St. George's University School of Medicine, True Blue, GRD.
Cureus. 2024 Jun 13;16(6):e62321. doi: 10.7759/cureus.62321. eCollection 2024 Jun.
Atrial fibrillation (AF) is the most common heart rhythm disorder, defined by an irregular and rapid heartbeat. It is the most prevalent cardiac arrhythmia in the United States, characterized by irregular heartbeats due to asynchrony between atrial and ventricular contractions. AF can be categorized as paroxysmal or persistent and, as such, poses significant health risks, including heart failure and stroke. Factors like age, sex, lifestyle, and existing health conditions elevate AF risk. There have been a lot of debates around AF risk management and its impact on prognosis. This literature review aims to explore the influence of addressing modifiable risk factors in AF patients on its morbidity and mortality, exploring various treatment options and their effectiveness. Current guidelines suggest rate control and anticoagulation for persistent AF with medications like beta blockers and non-vitamin K oral anticoagulants. Catheter ablation for rhythm control is contentious. Studies on supplemental treatments, lifestyle changes, and managing comorbidities show mixed results, necessitating further research for comprehensive treatment effectiveness in AF patients, which this literature review will discuss.
心房颤动(AF)是最常见的心律紊乱,其定义为心跳不规则且快速。它是美国最普遍的心律失常,其特征是由于心房和心室收缩不同步导致心跳不规则。AF可分为阵发性或持续性,因此会带来重大健康风险,包括心力衰竭和中风。年龄、性别、生活方式和现有健康状况等因素会增加AF风险。围绕AF风险管理及其对预后的影响存在很多争论。这篇文献综述旨在探讨针对AF患者可改变的风险因素对其发病率和死亡率的影响,探索各种治疗选择及其有效性。当前指南建议使用β受体阻滞剂和非维生素K口服抗凝剂等药物对持续性AF进行心率控制和抗凝治疗。用于节律控制的导管消融存在争议。关于补充治疗、生活方式改变和合并症管理的研究结果不一,因此需要进一步研究AF患者综合治疗的有效性,本文献综述将对此进行讨论。